the drug, called duvakitug, showed that 36.2% of low dose and 47.8% of high dose patients with ulcerative colitis achieved clinical remission compared with 20.45% on a placebo. The companies said ...
Mabpharm Limited (HK:2181) has released an update.Don't Miss Our Christmas Offers:Discover the latest stocks recommended by top Wall Street ...
Chesnot / Getty Images Teva Pharmaceuticals and Sanofi on Tuesday reported positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn's disease. The companies plan to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback